Literature DB >> 17087813

Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain.

P Gutierrez-Recacha1, D Chisholm, J M Haro, L Salvador-Carulla, J L Ayuso-Mateos.   

Abstract

OBJECTIVE: To estimate the cost-effectiveness of interventions for reducing the burden of schizophrenia in Spain.
METHOD: The study examined the cost-effectiveness of seven different types of clinical interventions at the level of Spanish population: i) current situation; ii) older antipsychotics alone; iii) new antipsychotics alone (risperidone); iv) older antipsychotics plus psychosocial treatment; v) new antipsychotics plus psychosocial treatment; vi) older antipsychotics plus case management and psychosocial treatment; vii) new antipsychotics plus case management and psychosocial treatment.
RESULTS: Interventions based on the combination of haloperidol with psychosocial treatment or psychosocial treatment plus case management proved to be the most efficient strategies.
CONCLUSION: The relatively modest additional cost of concurrent psychosocial treatment has significant health gains, thereby making such a combined strategy for schizophrenia more cost-effective than pharmacology alone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17087813     DOI: 10.1111/j.1600-0447.2006.00917.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  10 in total

1.  Spatial analysis to identify hotspots of prevalence of schizophrenia.

Authors:  Berta Moreno; Carlos R García-Alonso; Miguel A Negrín Hernández; Francisco Torres-González; Luis Salvador-Carulla
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-05-23       Impact factor: 4.328

2.  Caregiver's Burden, Coping, and Psycho-Education in Indian Households with Single- and Multiple-Affected Members with Schizophrenia.

Authors:  Satabdi Chakraborty; Triptish Bhatia; Carol Anderson; Vishwajit L Nimgaonkar; Smita N Deshpande
Journal:  Int J Ment Health       Date:  2013-11-21

3.  Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis.

Authors:  Dan Chisholm; Oye Gureje; Sandra Saldivia; Marcelo Villalón Calderón; Rajitha Wickremasinghe; Nalaka Mendis; Jose-Luis Ayuso-Mateos; Shekhar Saxena
Journal:  Bull World Health Organ       Date:  2008-07       Impact factor: 9.408

4.  Considering variables for the assignment of patients with schizophrenia to a case management programme.

Authors:  Laia Mas-Expósito; Juan Antonio Amador-Campos; Juana Gómez-Benito; Lluís Lalucat-Jo
Journal:  Community Ment Health J       Date:  2013-06-18

Review 5.  Treatment of the first episode of schizophrenia: an update on pharmacologic and psychological interventions.

Authors:  Benedicto Crespo-Facorro; Rocío Pérez-Iglesias; Cesar González-Blanch; Ignacio Mata
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

6.  Clinical case management for patients with schizophrenia with high care needs.

Authors:  Laia Mas-Expósito; Juan Antonio Amador-Campos; Juana Gómez-Benito; Lluís Mauri-Mas; Lluís Lalucat-Jo
Journal:  Community Ment Health J       Date:  2014-06-28

7.  Strengthening mental health systems in low- and middle-income countries: the Emerald programme.

Authors:  Maya Semrau; Sara Evans-Lacko; Atalay Alem; Jose Luis Ayuso-Mateos; Dan Chisholm; Oye Gureje; Charlotte Hanlon; Mark Jordans; Fred Kigozi; Heidi Lempp; Crick Lund; Inge Petersen; Rahul Shidhaye; Graham Thornicroft
Journal:  BMC Med       Date:  2015-04-10       Impact factor: 8.775

8.  Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR.

Authors:  Umberto Restelli; Manuel García-Goñi; Michal Lew-Starowicz; Pawel Mierzejewski; Sofia Silvola; Jacqueline Mayoral-van Son; Davide Croce; Paola Rocca; Benedicto Crespo-Facorro
Journal:  Clin Drug Investig       Date:  2020-09       Impact factor: 2.859

9.  Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development.

Authors:  Dean T Acheson; Elizabeth W Twamley; Jared W Young
Journal:  Front Neurosci       Date:  2013-06-18       Impact factor: 4.677

Review 10.  Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care.

Authors:  Wai Tong Chien; Sau Fong Leung; Frederick Kk Yeung; Wai Kit Wong
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-25       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.